Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients

Japanese Journal of Cancer Research

Volumn 91, Issue 2, 2000, Pages 190-198

  Kihara, Chikashi ^a,c   Seki, Toyokazu ^a   Furukawa, Yoichi ^a   Yamana, Hideaki ^b   Kimura, Yasutoshi ^c   Van Schaardenburgh, Pepijn ^a   Hirata, Koichi ^c   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Mutation; p53; Prognosis; Zinc binding domains

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0034054816     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00931.x     Document Type: Article

References (25)

1. Levine, A. J. p53, cellular gatekeeper for growth and division. Cell, 88, 323-331 (1997).
2. Weller, M. Predicting response to cancer chemotherapy: the role of p53. Cell. Tissue Res., 292, 435-445 (1998).
3. Borresen-Dale, A. L., Lothe, R. A., Meling, G. I., Hainaut, P., Rognum, T. O. and Skovlund, E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res., 4, 203-210 (1998).
4. Berns, E. M., van Staveren, I. L., Look, M. P., Smid, M., Klijn, J. G. and Foekens, J. A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br. J. Cancer, 77, 1130-1136 (1998).
5. Uchino, S., Saito, T., Inomata, M., Osawa, N., Chikuba, K., Etoh, K. and Kobayashi, M. Prognostic significance of the p53 mutation in esophageal cancer. Jpn. J. Clin. Oncol., 26, 287-292 (1996).
6. Casson, A. G., Tammemagi, M., Eskandarian, S., Redston, M., McLaughlin, J. and Ozcelik, H. p53 alterations in esophageal cancer: association with clinicopathological features, risk factors, and survival. Mol. Pathol., 51, 71-79 (1998).
7. Lam, K. Y., Tsao, S. W., Zhang, D., Law, S., He, D., Ma, L. and Wong, J. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: a prospective clinico-pathological study and survival analysis of 70 patients. Int. J. Cancer, 74, 212-219 (1997).
8. Shimada, Y., Imamura, M., Shibagaki, I., Tanaka, H., Miyahara, T., Kato, M. and Ishizaki, K. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann. Surg., 226, 162-168 (1997).
9. Ribeiro, U., Jr., Finkelstein, S. D., Safatle-Ribeiro, A. V., Landreneau, R. J., Clarke, M. R., Bakker, A., Swalsky, P. A., Gooding, W. E. and Posner, M. C. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer, 83, 7-18 (1998).
10. Sato, S., Nakamura, Y. and Tsuchiya, E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res., 54, 5652-5655 (1994).
11. Soong, R. and Iacopetta, B. J. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod. Pathol., 10, 252-358 (1997).
12. Kaplan, E. L. and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53, 457-481 (1958).
13. Cho, Y., Gorina, S., Jeffrey, P. D. and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355 (1994).
14. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
15. Goh, H. S., Yao, J. and Smith, D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55, 5217-5221 (1995).
16. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A. and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1, 1029-1034 (1995).
17. Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T. and Yokota, J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene, 18, 1007-1014 (1999).
18. Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, W. D. and Pari, F. F. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer, 73, 2147-2156 (1994).
19. Slebos, R. J., Baas, I. O., Clement, M., Polak, M., Mulder, J. W., van den Berg, F. M., Hamilton, S. R. and Offerhaus, G. J. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br. J. Cancer, 74, 165-171 (1996).
20. Rolley, N., Butcher, S. and Milner, J. Specific DNA binding by different classes of human p53 mutants. Oncogene, 11, 763-770 (1995).
21. Ludwig, R. L., Bates, S. and Vousden, K. H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol., 16, 4952-4960 (1996).
22. Ceraline, J., Deplanque, G., Duclos, B., Limacher, J. M., Hajri, A., Noel, F., Orvain, C., Frebourg, T., Klein-Soyer, C. and Bergerat, J. P. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int. J. Cancer, 75, 432-438 (1998).
23. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A. and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2, 811-814 (1996).
24. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B. and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13, 1971-1981 (1996).
25. Benhattar, J., Cerottini, J. P., Saraga, E., Metthez, G. and Givel, J. C. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer, 69, 190-192 (1996).